Evidence map›Paper›PMID 39330851›Full record

ArticleToxins2024

Neutralizing Nanobodies against Venoms from

Hiba Mejri, Rym Mokrani, Ayoub Ksouri, Mabrouk Seddik, Nour Awad, Gabriel Ayme, Thouraya Chagour, Ahlem Mokrani, Charraf Eddine Louchene, Imed Salhi and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hiba MejriLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.
Rym MokraniResearch and Development Laboratory, Institut Pasteur Algérie, University of Algiers 1, Algiers 16000, Algeria.
Ayoub KsouriLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.ORCID 0009-0008-2117-8154
Mabrouk SeddikLivestock and Wildlife Laboratory (LR16IRA04), Arid Lands Institute (I.R.A), University of Gabès, Medenine 4119, Tunisia.
Nour AwadChannel Receptors Unit, Université de Paris Cité, CNRS UMR 3571, Institut Pasteur, 75015 Paris, France.
Gabriel AymeAntibody Engineering Platform, C2RT, Université de Paris Cité, CNRS UMR 3528, Institut Pasteur, 75015 Paris, France.ORCID 0000-0002-0438-8095
Thouraya ChagourLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.
Ahlem MokraniResearch and Development Laboratory, Institut Pasteur Algérie, University of Algiers 1, Algiers 16000, Algeria.
Charraf Eddine LoucheneResearch and Development Laboratory, Institut Pasteur Algérie, University of Algiers 1, Algiers 16000, Algeria.ORCID 0000-0002-0877-716X
Imed SalhiLivestock and Wildlife Laboratory (LR16IRA04), Arid Lands Institute (I.R.A), University of Gabès, Medenine 4119, Tunisia.
Rahma Ben AbderrazekLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.
Rym Ben KhalifaLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.ORCID 0000-0002-6944-481X
Zakaria BenlasfarLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.ORCID 0009-0007-7583-1887
Pierre-Jean CorringerChannel Receptors Unit, Université de Paris Cité, CNRS UMR 3571, Institut Pasteur, 75015 Paris, France.
Mohamed HammadiLivestock and Wildlife Laboratory (LR16IRA04), Arid Lands Institute (I.R.A), University of Gabès, Medenine 4119, Tunisia.ORCID 0000-0003-4178-0763
Selma DjilaniResearch and Development Laboratory, Institut Pasteur Algérie, University of Algiers 1, Algiers 16000, Algeria.
Pierre LafayeAntibody Engineering Platform, C2RT, Université de Paris Cité, CNRS UMR 3528, Institut Pasteur, 75015 Paris, France.ORCID 0000-0002-5761-1342
Balkiss Bouhaouala-ZaharLaboratory of Venoms and Theranostic Applications (LR20IPT01), Place Pasteur, BP704, Pasteur Institute of Tunis, Université Tunis el Manar, Tunis 1002, Tunisia.ORCID 0000-0003-3147-245X

Funding

venomatics 2018-20Wellcome TrustWellcome Trust 221716/Z/20/Z
6 · The paper itself

Abstract

Snakebite envenoming (SBE) remains a severely neglected public health issue, particularly affecting tropical and subtropical regions, with Africa experiencing an estimated 435,000 to 580,000 snakebites annually, leading to high morbidity and mortality rates, especially across Africa and Asia. Recognized as a Neglected Tropical Disease, SBE management is further complicated by the inadequate efficacy of current antivenom treatments. Of particular concern are cobras (

Indexed as

Antibodies, NeutralizingAntiveninsElapid VenomsSingle-Domain AntibodiesAfrica, NorthernAnimalsCamelusMaleMiceNajaNaja najaSnake BitesAntibodies, NeutralizingAntiveninsElapid VenomsSingle-Domain Antibodiescobra venomLD50Naja hajenanobodyneutralizing capacity

Identifiers

PMID39330851
PMCPMC11435604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.